Feb 11, 2026 04:16PM
Jan 12, 2026 07:00AM
Jan 12, 2026 07:00AM
Jan 8, 2026 07:07AM
Jan 8, 2026 07:00AM
Nov 19, 2025 02:55AM
Nov 19, 2025 02:55AM Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
Nov 6, 2025 07:05AM
Nov 6, 2025 07:05AM
Oct 29, 2025 04:05PM
Oct 23, 2025 02:54AM
Oct 22, 2025 04:05PM
Oct 21, 2025 07:05AM
Oct 21, 2025 07:05AM Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
Sep 14, 2025 08:00PM
Aug 19, 2025 07:09AM
Aug 19, 2025 07:08AM
Jul 23, 2025 04:05PM
Jun 25, 2025 10:13AM
Jun 25, 2025 07:03AM
Apr 23, 2025 04:05PM Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Mar 26, 2025 07:05AM
Mar 11, 2025 07:03AM
Mar 11, 2025 07:03AM
Feb 5, 2025 04:05PM
Jan 8, 2025 07:03AM
Jan 8, 2025 07:03AM
Nov 22, 2024 02:25AM B.Riley Starts Viking Therapeutic (VKTX) at Buy
Nov 7, 2024 07:00AM
Nov 4, 2024 06:30AM
Nov 4, 2024 06:30AM
Oct 28, 2024 04:05PM
Oct 23, 2024 04:05PM
Aug 6, 2024 04:01PM
Jul 24, 2024 04:33PM Viking Therapeutics (VKTX) to advance VK2735 into Phase 3 program for obesity
Jul 24, 2024 04:05PM
May 7, 2024 04:00PM
Apr 24, 2024 04:05PM
Mar 26, 2024 07:03AM
Mar 26, 2024 07:03AM
Mar 15, 2024 06:42AM
Feb 27, 2024 12:06PM Viking Therapeutic (VKTX) PT Raised to $80 at Stifel, '“Best-in-Class” Profile of Injectable VK2735 Stands Firm'
Feb 27, 2024 08:40AM
Feb 27, 2024 07:03AM
Feb 27, 2024 07:03AM
Feb 27, 2024 07:00AM
Nov 8, 2023 04:01PM
Oct 23, 2023 07:05AM
Oct 17, 2023 04:22PM Viking Therapeutics (VKTX) Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation
Oct 17, 2023 04:05PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All